&lt;p&gt;Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer&lt;/p&gt;

Bacinschi, Xenia; Zgură, Anca; Safta, Inga; Anghel, Rodica

doi:10.2147/cmar.s274104

Cited by 7 publications

(5 citation statements)

References 36 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another significant clinical measure for determining the stage and prognosis of breast cancer is the p53 index. This index is based on the percentage of positive p53 staining samples, where more than 50% indicates a good prognosis or appropriate treatment, while less than 22% suggests a poor prognosis or inadequate treatment (Bacinschi et al, 2020). Patients with TNBC tumors have a greater sensitivity to chemotherapy using anthracyclines like DOX and exhibit a higher rate of favorable pathological response compared with other breast tumors, as indicated by the immunohistochemical marker Ki-67.…”

Section: Discussionmentioning

confidence: 99%

Bee Pollen and Doxorubicin by Synergistic Effects Inhibit the Proliferation of Breast Tumors in 4T1 Tumor-bearing BALB/c Mice: A Biochemical, Immunohistochemical,and Molecular Approach

2023

Pharmacognosy Magazine

View full text Add to dashboard Cite

Objectives This study investigated the effects of BP and doxorubicin (DOX) on 4T1 tumor cells in a mouse model. Materials and Methods After inducing breast tumors, 70 4T1-tumor-bearing BALB/c mice were divided into seven groups ( n = 10/group). The groups were treated with DOX and BP for 35 days. On the 36th day, blood was taken from the heart, and serum was separated to measure levels of cytokines, estrogen, progesterone, testosterone, and nitric oxide. Antioxidant enzyme activities, as well as tissue ferric-reducing antioxidant power (FRAP) and malondialdehyde (MDA) levels, were evaluated. The expression of apoptotic genes and metastasis was measured using real-time polymerase chain reaction (PCR), while the expression of apoptotic proteins was evaluated using Western blotting. Finally, Ki-67 and p-53 were examined using immunohistochemistry to determine apoptosis. Results The study found that BP, with its synergistic effects with DOX, reduced the volume of tumors and increased the expression of apoptotic genes and proteins. In a dose-dependent manner, groups receiving BP and DOX with their synergistic effects reduced the level of estrogen and nitric oxide and also reduced the level of pro-inflammatory cytokines. BP along with DOX increased serum interferon-γ (IFN-γ) levels. Tumor tissue FRAP and thiobarbituric acid reactive substances (TBARS) levels increased in BP-treated groups. Ki-67 and Bcl-2 proliferation markers levels decreased, and p53 levels increased in 4T1-breast tumors. Conclusion The study concluded that BP with its synergistic effects along with DOX has the ability to suppress the growth of tumors and can also inhibit the oxidative damage of DOX.

show abstract

Section: Discussionmentioning

confidence: 99%

Bee Pollen and Doxorubicin by Synergistic Effects Inhibit the Proliferation of Breast Tumors in 4T1 Tumor-bearing BALB/c Mice: A Biochemical, Immunohistochemical,and Molecular Approach

2023

Pharmacognosy Magazine

View full text Add to dashboard Cite

show abstract

“…In recent years, TNBC has become a hot spot for clinical research in recent years due to an increase in incidence and a younger age group [ 9 ]. Studies have shown that deletion or mutation of breast cancer1/2(BRCA1/2) is closely associated with the development of TNBC.…”

Section: Discussionmentioning

confidence: 99%

A case report and literature review on a rare subtype of triple-negative breast cancer in children

Shi,

Zhang,

et al. 2023

BMC Pediatr

View full text Add to dashboard Cite

Background Triple-negative breast cancer (TNBC) is a type of breast tumor with a poor prognosis because it lacks or expresses low levels of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2). TNBC is more common in middle-aged and older women, and cases of TNBC in children are rarely reported. This is the only case of childhood SBC in our hospital in more than 70 years, and the disease is extremely rare internationally. We analyzed and studied the disease and TNBC from both clinical and pathological aspects and found that SBC is very different from TNBC. Case presentation We report a case of secretory breast cancer (SBC), a subtype of TNBC, in an 8-year-old girl from our institution. The child presented with a single mass in the left breast only, with no skin rupture and no enlargement of the surrounding lymph nodes. The child underwent two surgeries and was followed up for one year with a good prognosis. Conclusions SBC is highly prevalent among the multiple pathological types of pediatric breast cancer. Almost all pediatric SBC patients are characterized by the ETV6-NTRK3 fusion gene, which has a good prognosis and a 10-year survival rate of more than 90% when compared with other TNBC subtypes. According to the patient, we performed local mass resection and a postoperative pathological diagnosis of SBC (a subtype of BL-TNBC). The TNBC case had a good prognosis and differed from basal TNBC in several aspects, including clinical presentation, treatment, and prognosis. It is necessary to exclude SBC from BL-type TNBC, enhance understanding of the disease, and individualize the treatment plan, so as to avoid medical errors.

show abstract

“…Patients who are positive for these receptors have a more favorable prognosis and a higher survival rate (30). By contrast, patients with triple-negative breast cancer, who are negative for ER and PR and HER2 protein receptors have a more unfavorable prognosis and hormone therapy is ineffective in this case (26,31). Women with only one type of positive receptor but with the other negative, can benefit from hormone therapy although the therapeutic response is variable (32,33).…”

Section: Discussionmentioning

confidence: 99%

Impact of modern personalized treatment of breast cancer on surgical attitude and outcomes

et al. 2021

View full text Add to dashboard Cite

<p>Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer</p>

Cited by 7 publications

References 36 publications

Bee Pollen and Doxorubicin by Synergistic Effects Inhibit the Proliferation of Breast Tumors in 4T1 Tumor-bearing BALB/c Mice: A Biochemical, Immunohistochemical,and Molecular Approach

Bee Pollen and Doxorubicin by Synergistic Effects Inhibit the Proliferation of Breast Tumors in 4T1 Tumor-bearing BALB/c Mice: A Biochemical, Immunohistochemical,and Molecular Approach

A case report and literature review on a rare subtype of triple-negative breast cancer in children

Impact of modern personalized treatment of breast cancer on surgical attitude and outcomes

Contact Info

Product

Resources

About